Javascript must be enabled to continue!
Analysis of topoisomerase II‐mediated DNA cleavage of the c‐myc gene during HL60 differentiation
View through CrossRef
We have investigated the effect of mAMSA, a potent topoisomerase II inhibitor, on the c‐myc proto‐oncogene of the acute promyelocytic leukemia HL60 cell line during its differentiation. When HL60 cells were induced by dimethylsulfoxide (DMSO) to terminally differentiate, a rapid drop in the level of cmyc mRNA was observed, followed by an arrest of cell proliferation. In contrast, the level of topoisomerase II mRNA was transiently increased with a maximum at 6 h after DMSO addition and was then completely abolished after 48 h, indicating that topoisomerase II is activated during the onset of HL60 differentiation. In exponentially growing cells, treatment by mAMSA results in the formation of topoisomerase II‐mediated double strand DNA breaks in the c‐myc gene at positions where topoisomerase II would normally nick and reseal the two strands. In HL60 cells treated with both mAMSA and DMSO, the sites in the cmyc gene at which mAMSA had induced cleavage were not altered. However, a DNA cleavage site located at the end of the first c‐myc exon (position +3100), was strongly stimulated by mAMSA and DMSO treatment. This site fell within a DNase I hypersensitive region encompassing the MYC intron factor 1 (MIF1) binding site, where transcription elongation is normally blocked during differentiation. These data indicate that a change of topoisomerase II binding to critical regulatory region of the c‐myc gene is associated with the downregulation of this gene during differentiation.
Title: Analysis of topoisomerase II‐mediated DNA cleavage of the c‐myc gene during HL60 differentiation
Description:
We have investigated the effect of mAMSA, a potent topoisomerase II inhibitor, on the c‐myc proto‐oncogene of the acute promyelocytic leukemia HL60 cell line during its differentiation.
When HL60 cells were induced by dimethylsulfoxide (DMSO) to terminally differentiate, a rapid drop in the level of cmyc mRNA was observed, followed by an arrest of cell proliferation.
In contrast, the level of topoisomerase II mRNA was transiently increased with a maximum at 6 h after DMSO addition and was then completely abolished after 48 h, indicating that topoisomerase II is activated during the onset of HL60 differentiation.
In exponentially growing cells, treatment by mAMSA results in the formation of topoisomerase II‐mediated double strand DNA breaks in the c‐myc gene at positions where topoisomerase II would normally nick and reseal the two strands.
In HL60 cells treated with both mAMSA and DMSO, the sites in the cmyc gene at which mAMSA had induced cleavage were not altered.
However, a DNA cleavage site located at the end of the first c‐myc exon (position +3100), was strongly stimulated by mAMSA and DMSO treatment.
This site fell within a DNase I hypersensitive region encompassing the MYC intron factor 1 (MIF1) binding site, where transcription elongation is normally blocked during differentiation.
These data indicate that a change of topoisomerase II binding to critical regulatory region of the c‐myc gene is associated with the downregulation of this gene during differentiation.
Related Results
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract
Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Abstract
Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with ...
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Abstract
Background: The diagnosis of Burkitt lymphoma (BL) is usually based on histopathology (HP), immunohistochemistry (IHC), fluorescence in situ hybridization (...
Topoisomerase Assays
Topoisomerase Assays
AbstractTopoisomerases are enzymes that play essential roles in DNA replication, transcription, chromosome segregation, and recombination. All cells have two major forms of DNA top...
Abstract 563: WEE1 reinforces C-MYC driven oncogenic programs through GSK3ß inhibition.
Abstract 563: WEE1 reinforces C-MYC driven oncogenic programs through GSK3ß inhibition.
Abstract
Background:
Esophageal adenocarcinoma (EAC) remains a lethal malignancy with a 5-year survival rate below 20%. T...
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract
Liver cancer incidence rates have more than tripled in the last 40 years and is projected to increase more than 40% in the next decade. Although progress ha...

